MicroRNA-381 in Human Cancer: Its Involvement in Tumour Biology and Clinical Applications Potential

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2022 Jan 11

PMID 35014178

Authors

Huanhuan Sha

Yujie Gan

Feng Xu

Yue Zhu

Renrui Zou

Weiwei Peng

Zhiya Wu

Rong Ma

Jianzhong Wu

Jifeng Feng

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the post-transcriptional level. MiRNAs are involved in the development and progression of a wide range of cancers. Among such cancer-associated miRNAs, miR-381 has been a major focus of research. The expression pattern and role of miR-381 vary among different cancer types. MiR-381 modulates various cellular behaviours in cancer, including proliferation, apoptosis, cell cycle progression, migration and invasion. MiR-381 is also involved in angiogenesis and lymphangiogenesis, as well as in the resistance to chemotherapy and radiotherapy. MiR-381 itself is regulated by several factors, such as long noncoding RNAs, circular RNAs and cytokines. Aberrant expression of miR-381 in blood samples indicates that it can be used as a diagnostic marker in cancer. Tissue miR-381 expression may serve as a prognostic factor for the clinicopathological characteristics of cancers and survival of patients. Metformin and icaritin regulate miR-381 expression and present anticancer properties. This review comprehensively summarizes the effect of miR-381 on tumour biological behaviours, as well as the clinical application potential of miR-381 for the treatment of cancer.

Citing Articles

EIF4A3-mediated oncogenic circRNA hsa_circ_0001165 advances esophageal squamous cell carcinoma progression through the miR-381-3p/TNS3 pathway.

Zhang X, Bian Y, Li Q, Yu C, Gao Y, Tian B Cell Biol Toxicol. 2024; 40(1):84.

PMID: 39382613 PMC: 11481643. DOI: 10.1007/s10565-024-09927-9.

Mir-381-3p aggravates ovariectomy-induced osteoporosis by inhibiting osteogenic differentiation through targeting KLF5/Wnt/β-catenin signaling pathway.

Zhao Y, Liu J, Zhang Y, Liang M, Li R, Song Y J Orthop Surg Res. 2024; 19(1):480.

PMID: 39152444 PMC: 11330013. DOI: 10.1186/s13018-024-04992-6.

miRNAs in radiotherapy resistance of cancer; a comprehensive review.

Al-Hawary S, Jasim S, Altalbawy F, Kumar A, Kaur H, Pramanik A Cell Biochem Biophys. 2024; 82(3):1665-1679.

PMID: 38805114 DOI: 10.1007/s12013-024-01329-2.

miRNA-381 regulates renal cancer stem cell properties and sunitinib resistance via targeting SOX4.

Lu X, Gao W, Li J, Qin S Biochem Biophys Rep. 2023; 36:101566.

PMID: 37965067 PMC: 10641571. DOI: 10.1016/j.bbrep.2023.101566.

miRNAs, Mesenchymal Stromal Cells and Major Neoplastic and Inflammatory Skin Diseases: A Page Being Written: A Systematic Review.

Di Vincenzo M, Diotallevi F, Piccirillo S, Carnevale G, Offidani A, Campanati A Int J Mol Sci. 2023; 24(10).

PMID: 37239847 PMC: 10217999. DOI: 10.3390/ijms24108502.

References

Gao S, Cai Y, Zhang H, Hu F, Hou L, Xu Q . Long noncoding RNA DLEU1 aggravates pancreatic ductal adenocarcinoma carcinogenesis via the miR-381/CXCR4 axis. J Cell Physiol. 2018; 234(5):6746-6757. DOI: 10.1002/jcp.27421. View

Chan Y, Yu Y, Wang G, Wang C, Zhang D, Wang X . Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma. Med Sci Monit. 2019; 25:5181-5190. PMC: 6642673. DOI: 10.12659/MSM.915524. View

Rui X, Gu T, Pan H, Shao S, Shao H . MicroRNA-381 suppresses proliferation and invasion of prostate cancer cells through downregulation of the androgen receptor. Oncol Lett. 2019; 18(2):2066-2072. PMC: 6607051. DOI: 10.3892/ol.2019.10471. View

Mi H, Wang X, Wang F, Li L, Zhu M, Wang N . miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN. Eur J Pharmacol. 2018; 839:66-75. DOI: 10.1016/j.ejphar.2018.09.024. View

Mocavini I, Pippa S, Licursi V, Paci P, Trisciuoglio D, Mannironi C . JARID1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer. Cancer Sci. 2018; 110(4):1232-1243. PMC: 6447846. DOI: 10.1111/cas.13925. View

Matsumura N, Huang Z, Baba T, Lee P, Barnett J, Mori S . Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res. 2009; 7(2):210-20. PMC: 2675878. DOI: 10.1158/1541-7786.MCR-08-0255. View

Shang A, Zhou C, Bian G, Chen W, Lu W, Wang W . miR-381-3p restrains cervical cancer progression by downregulating FGF7. J Cell Biochem. 2018; 120(1):778-789. DOI: 10.1002/jcb.27438. View

Sha H, Gan Y, Xu F, Zhu Y, Zou R, Peng W . MicroRNA-381 in human cancer: Its involvement in tumour biology and clinical applications potential. J Cell Mol Med. 2022; 26(4):977-989. PMC: 8831973. DOI: 10.1111/jcmm.17161. View

Hu W, Chen P, Chen J, Wu Y, Liu P, Lu C . Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer. Oncotarget. 2017; 8(37):62248-62260. PMC: 5617502. DOI: 10.18632/oncotarget.19273. View

10.

Zhang P, Pei X, Li K, Jin L, Wang F, Wu J . Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019; 18(1):179. PMC: 6900862. DOI: 10.1186/s12943-019-1111-2. View

11.

Al-Eryani L, Jenkins S, States V, Pan J, Malone J, Rai S . miRNA expression profiles of premalignant and malignant arsenic-induced skin lesions. PLoS One. 2018; 13(8):e0202579. PMC: 6095593. DOI: 10.1371/journal.pone.0202579. View

12.

Li J, Ying Y, Xie H, Jin K, Yan H, Wang S . Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer. FASEB J. 2018; 33(1):1374-1388. DOI: 10.1096/fj.201800667R. View

13.

Anadon C, Guil S, Simo-Riudalbas L, Moutinho C, Setien F, Martinez-Cardus A . Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene. 2015; 35(33):4407-13. PMC: 4842009. DOI: 10.1038/onc.2015.469. View

14.

Wang Y, Xu X, Yu S, Jeong K, Zhou Z, Han L . Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017; 27(7):1112-1125. PMC: 5495064. DOI: 10.1101/gr.219741.116. View

15.

Mallela A, Nishikura K . A-to-I editing of protein coding and noncoding RNAs. Crit Rev Biochem Mol Biol. 2012; 47(6):493-501. DOI: 10.3109/10409238.2012.714350. View

16.

Fang Z, Zhong M, Wang Y, Yuan X, Guo H, Yao Y . miR‑381 and miR‑489 suppress cell proliferation and invasion by targeting CUL4B via the Wnt/β‑catenin pathway in gastric cancer. Int J Oncol. 2018; 54(2):733-743. DOI: 10.3892/ijo.2018.4646. View

17.

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View

18.

Tian C, Li J, Ren L, Peng R, Chen B, Lin Y . MicroRNA-381 serves as a prognostic factor and inhibits migration and invasion in non-small cell lung cancer by targeting LRH-1. Oncol Rep. 2017; 38(5):3071-3077. DOI: 10.3892/or.2017.5956. View

19.

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

20.

Chen B, Duan L, Yin G, Tan J, Jiang X . miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother. 2013; 25(4):229-38. DOI: 10.1179/1973947813Y.0000000092. View